ADAMTSL3

Across TCGA pan-cancer cohorts, ADAMTSL3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAMTSL3 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADAMTSL3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ADAMTSL3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where ADAMTSL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.919	0.642	.018	16	view →
LSCC	DFS	Median	III,IV	0.460	0.894	.009	7	view →
UCEC	OS	Median	III,IV	0.315	0.915	.031	4	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →
CCRCC	DFS	Quartile	II,III,IV	0.907	0.452	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADAMTSL3–PDAC (OS)

Open the PDAC breakdown →